Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

NCT05787496 is registered in ClinicalTrials.gov with NextCure, Inc. as lead sponsor.

NCT NCT05787496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05787496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Lead sponsor
NextCure, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
February 28, 2023
Completion date
January 31, 2025
Enrollment
28 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory acute myeloid leukemia, relapsed or refractory chronic myelomonocytic leukemia, relapsed or refractory myelodysplastic syndrome